SAN ANTONIO — Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual …
SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Details of these study results…
Breast cancer tumors that stop responding to the drug tamoxifen actually change their cellular characteristics and become responsive to other types of drugs, including Herceptin, according to oncologists at the Duke Comprehensive Cancer Center. “In the process of becoming resistant to tamoxifen, the tumors alter their qualities and become receptive to Herceptin and other drugs that target the HER-2 receptor,” said Kimberly Blackwell, M.D., assistant professor of oncology at Duke.
A new clinical trial has shown that reducing the interval between successive doses of a commonly used chemotherapy regimen improves survival in women whose breast cancer has spread to the lymph nodes. While previous research has evaluated the use of various forms of “dose dense” chemotherapy, this is the first major controlled study to show a clear survival benefit for women with node-positive breast cancer.